Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489170 | 1.00 | NOS1 (0.38) | NOS1TSHR | |
| SCHEMBL166711 | 1.00 | NOS1 (0.38) | NOS1TSHR | |
| SCHEMBL14389726 | 0.79 | NOS1 (0.32) | NOS1 | |
| SCHEMBL347809 | 0.79 | — | — | |
| SCHEMBL13053377 | 0.79 | NOS1 (0.32) | NOS1 | |
| SCHEMBL23960910 | 0.79 | — | — | |
| SCHEMBL23829836 | 0.77 | — | — | |
| SCHEMBL25481131 | 0.77 | — | — | |
| SCHEMBL1094661 | 0.75 | — | — | |
| SCHEMBL16439241 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363923-B1 | RHODIUM AND IRIDIUM COMPLEXES | MERCK PATENT GMBH (DE) | 2009-04-01 | — | — | EP | claimed |
| US-7125998-B2 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2006-10-24 | — | — | US | claimed |
| EP-1562964-B1 | PALLADIUM AND PLATINUM COMPLEXES | MERCK PATENT GMBH (DE) | 2006-07-19 | — | — | EP | claimed |
| EP-1562964-A1 | PALLADIUM AND PLATINUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2005-08-17 | — | — | EP | claimed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| WO-2004041835-A1 | PALLADIUM AND PLATINUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-21 | — | — | WO | claimed |
| EP-1363923-A1 | RHODIUM AND IRIDIUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2003-11-26 | — | — | EP | claimed |
| WO-2002068435-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-09-06 | — | — | WO | claimed |
| US-12635401-B2 | Metal complexes | UDC Ireland (IE) | 2026-05-19 | — | — | US | disclosed |
| EP-4069709-B1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-12250871-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2025-03-11 | — | — | US | disclosed |
| US-20240260448-A1 | Metal Complexes | UDC IRELAND LIMITED (IE) | 2024-08-01 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20050031900-A1 | Aromatic monomer-and conjugated polymer-metal complexes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004041835-A1 | PALLADIUM AND PLATINUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037836-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
| EP-1363923-A1 | RHODIUM AND IRIDIUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002068435-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635401-B2 | Metal complexes | SCO2, SOD1, NR4A1 | NOS1 1651/4885TSHR 819/4885 |
| US-20040138455-A1 | Rhodium and iridium complexes | RPIA, MPI, INPP5B | NOS1 3525/4885TSHR 2857/4885 |
| US-12250871-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | NOS1 3933/4885TSHR 4537/4885 |
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | NOS1 3890/4885TSHR 3800/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | NOS1 916/4885TSHR 4796/4885 |
| US-20240260448-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | NOS1 3883/4885TSHR 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.